Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

The global Burn Care Market is projected to be valued at USD 2.79 billion in 2024 and reach US$ 4.23 billion by 2030, growing ...

Given this risk, we thought we'd take a look at whether MDJM (NASDAQ:UOKA) shareholders should be worried about its cash burn ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether XBiotech (NASDAQ:XBIT) shareholders ...

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company announced a ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones. Find out why CAPR stock ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

Allan Reine, the company's chief financial officer, has been named CEO and will become a member of the board. Jeff Marrazzo, another director, has been named executive chair. Prime's shares fell 8.2% ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments ...

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025a7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck ...